Patients with MetB bone metastases have reduced AR levels and morphological signs of a reactive stroma response already in their primary tumor stroma, something previously associated with poor response to ADT and a poor prognosis (Wikström et al., 2009). The gene discussed is AR; the disease is neoplasm.